- Bernard J. Birkett, CFO of West Pharmaceutical Services (WST, Financial), announces retirement plans for 2025.
- Shane Campbell appointed as Senior VP, Chief Proprietary Segment Officer, effective May 5, 2025.
- Birkett played a crucial role during the pandemic and other financial challenges.
West Pharmaceutical Services, Inc. (WST), a prominent provider of injectable drug solutions, has announced significant changes in its executive leadership team. Bernard J. Birkett, the current Senior Vice President and Chief Financial Officer, has revealed his intention to retire within the year. He has been a key figure in the company since June 2018, overseeing various challenges including the global pandemic and destocking issues, and will remain as CFO until a suitable successor is found.
In a strategic leadership move, Shane Campbell has been appointed as Senior Vice President, Chief Proprietary Segment Officer, with his tenure commencing on May 5, 2025. Campbell transitions from Carlisle Companies Inc., where he was the Chief Commercial Officer for the Construction Materials division. His extensive experience, including a 20-year career at DuPont in senior global roles, is expected to drive West's proprietary product strategy forward efficiently.
Eric M. Green, the President, CEO, and Chair of the Board of West, acknowledged Birkett's invaluable contributions, highlighting his leadership during critical periods, particularly amid the challenges posed by the pandemic and the introduction of GLP-1s. Green expressed optimism about the future with Campbell's strategic vision contributing to the company’s long-term growth.
Additionally, West Pharmaceutical Services (WST, Financial) has reported its first-quarter 2025 financial results and will discuss these outcomes along with future business expectations during a scheduled conference call. Participants can register for the call to inquire further about the company's strategies and financial outlook.
